D
Devi SenGupta
Researcher at University of California, San Francisco
Publications - 39
Citations - 3997
Devi SenGupta is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Tenofovir alafenamide & T cell. The author has an hindex of 22, co-authored 38 publications receiving 2935 citations. Previous affiliations of Devi SenGupta include Harvard University & University of Washington.
Papers
More filters
Journal ArticleDOI
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Jason D Goldman,David C. Lye,David S.C. Hui,Kristen M. Marks,Raffaele Bruno,Rocio Montejano,Christoph D. Spinner,Massimo Galli,Mi Young Ahn,Ronald Nahass,Yao Shen Chen,Devi SenGupta,Robert H. Hyland,Anu Osinusi,Huyen Cao,Christiana Blair,Xuelian Wei,Anuj Gaggar,Diana M. Brainard,William J. Towner,Jose Muñoz,Kathleen M. Mullane,Francisco M. Marty,Karen T. Tashima,George A. Diaz,Aruna Subramanian +25 more
TL;DR: In patients with severe Covid-19 not requiring mechanical ventilation, a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia, the magnitude of benefit cannot be determined.
Journal ArticleDOI
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Christoph D. Spinner,Robert L. Gottlieb,Gerard J. Criner,José Ramón Arribas López,Anna Maria Cattelan,Alex Soriano Viladomiu,Onyema Ogbuagu,Prashant Malhotra,Kathleen M. Mullane,Antonella Castagna,Louis Yi Ann Chai,Meta Roestenberg,Owen Tak Yin Tsang,Enos Bernasconi,Paul Le Turnier,Shan-Chwen Chang,Devi SenGupta,Robert H. Hyland,Anu Osinusi,Huyen Cao,Christiana Blair,Hongyuan Wang,Anuj Gaggar,Diana M. Brainard,Mark J. W. McPhail,Sanjay Bhagani,Mi Young Ahn,Arun J. Sanyal,Gregory D. Huhn,Francisco M. Marty +29 more
TL;DR: Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment, but the difference was of uncertain clinical importance.
Journal ArticleDOI
Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities
Nicole Frahm,Bette T. Korber,Bette T. Korber,C. M. Adams,James J. Szinger,Rika Draenert,Marylyn M. Addo,Margaret E. Feeney,Karina Yusim,Kaori Sango,Nancy V. Brown,Devi SenGupta,Alicja Piechocka-Trocha,T. Simonis,F. M. Marincola,Alysse G. Wurcel,David Stone,Christopher J. Russell,P. Adolf,Daniel E. Cohen,Timothy Roach,A. StJohn,Ashok Khatri,K. Davis,James I. Mullins,Philip J. R. Goulder,Bruce D. Walker,Christian Brander +27 more
TL;DR: Factors that contribute to the immunogenicity of these highly targeted and relatively conserved sequences in HIV that may represent promising vaccine candidates for ethnically heterogeneous populations are identified.
Journal ArticleDOI
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul E. Sax,Anton Pozniak,M. Luisa Montes,Ellen Koenig,Edwin DeJesus,Hans Jürgen Stellbrink,Andrea Antinori,Kimberly A. Workowski,Jihad Slim,Jacques Reynes,Will Garner,Joseph M. Custodio,Kirsten L. White,Devi SenGupta,Andrew T. A. Cheng,Erin Quirk +15 more
TL;DR: Results are reported from a study comparing initial HIV-1 treatment with bictegravir with a novel INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug interactions, showing non-inferiority of the bictricitabine regimen to the dolutegravIR regimen.
Journal ArticleDOI
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak,Jose R. Arribas,Joseph Gathe,Samir K. Gupta,Frank A. Post,Mark Bloch,Anchalee Avihingsanon,Gordon Crofoot,Paul M. Benson,Kenneth A. Lichtenstein,Moti Ramgopal,Ploenchan Chetchotisakd,Joseph M. Custodio,Michael E. Abram,Xuelian Wei,Andrew K. Cheng,Scott McCallister,Devi SenGupta,Marshall W. Fordyce +18 more
TL;DR: These data support the efficacy and safety of once daily E/C/F/TAF in HIV+ patients with mild or moderate renal impairment without dose adjustment and Proteinuria, albuminuria and bone mineral density significantly improved.